Cargando…

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers

Preclinical studies have indicated that T-cell immunoglobulin and ITIM domain (TIGIT) can substantially attenuate anti-tumoral immune responses. Although multiple clinical studies have evaluated the significance of TIGIT in patients with solid cancers, their results remain inconclusive. Thus, we con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosseinkhani, Negar, Shadbad, Mahdi Abdoli, Asghari Jafarabadi, Mohammad, Karim Ahangar, Noora, Asadzadeh, Zahra, Mohammadi, Seyede Momeneh, Lotfinejad, Parisa, Alizadeh, Nazila, Brunetti, Oronzo, Fasano, Rossella, Silvestris, Nicola, Baradaran, Behzad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508743/ https://www.ncbi.nlm.nih.gov/pubmed/34638729 http://dx.doi.org/10.3390/ijms221910389

Ejemplares similares

A Systematic Review to Clarify the Prognostic Values of CD44 and CD44(+)CD24(-) Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead
por: Abdoli Shadbad, Mahdi, et al.
Publicado: (2021)

A Systematic Review of the Tumor-Infiltrating CD8(+) T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology
por: Shadbad, Mahdi Abdoli, et al.
Publicado: (2021)

The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis
por: Abdoli Shadbad, Mahdi, et al.
Publicado: (2021)

A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study
por: Shadbad, Mahdi Abdoli, et al.
Publicado: (2022)

The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

Anti-TIGIT therapies for solid tumors: a systematic review
por: Rousseau, A., et al.
Publicado: (2023)

A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery
por: Shadbad, Mahdi Abdoli, et al.
Publicado: (2021)

Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study
por: Lotfinejad, Parisa, et al.
Publicado: (2020)

Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy
por: Amir Taghavi, Bita, et al.
Publicado: (2022)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis
por: Xiao, Kunmin, et al.
Publicado: (2021)

Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy
por: Fasano, Rossella, et al.
Publicado: (2021)

Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
por: Hosseinkhani, Negar, et al.
Publicado: (2020)

A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine
por: Abdoli Shadbad, Mahdi, et al.
Publicado: (2022)

Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
por: Yang, Fan, et al.
Publicado: (2023)

The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review
por: Ahangar, Noora Karim, et al.
Publicado: (2021)

TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

Targeting TGF-β-Mediated SMAD Signaling Pathway via Novel Recombinant Cytotoxin II: A Potent Protein from Naja naja oxiana Venom in Melanoma
por: Derakhshani, Afshin, et al.
Publicado: (2020)

Mechanisms of TIGIT-driven immune suppression in cancer
por: Kurtulus, Sema, et al.
Publicado: (2014)

Expression of the immune checkpoint receptor TIGIT in seminoma
por: Hinsch, Andrea, et al.
Publicado: (2019)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

TIGIT in Lung Cancer: Potential Theranostic Implications
por: Pescia, Carlo, et al.
Publicado: (2023)

Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and Development of Colorectal Cancer: Time to Overcome the Challenging Barriers?
por: Gholizadeh, Mahsa, et al.
Publicado: (2021)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis
por: Li, Sicong, et al.
Publicado: (2022)

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer
por: Blessin, Niclas C., et al.
Publicado: (2019)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

Targeting the “PVR–TIGIT axis” with immune checkpoint therapies
por: Gorvel, Laurent, et al.
Publicado: (2020)

TIGIT limits immune pathology during viral infections
por: Schorer, Michelle, et al.
Publicado: (2020)

Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
por: Lucca, Liliana E., et al.
Publicado: (2020)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

Discovery of TIGIT inhibitors based on DEL and machine learning
por: Xiong, Feng, et al.
Publicado: (2022)

Expression and Clinical Significance of TIGIT in Primary Breast Cancer
por: Tang, Limin, et al.
Publicado: (2023)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer
por: Maas, Ralph Ja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_au4qkto63qiud4eh9gvte3nmbr